Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision....

Full description

Bibliographic Details
Main Authors: Sonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2018-02-01
Series:Drugs in Context
Subjects:
case report
complete remission
dabrafenib
drug combination
melanoma
neoplasm metastasis
vemurafenib
Online Access:http://www.drugsincontext.com/treatment-combined-dabrafenib-trametinib-brafv600e-mutated-metastatic-malignant-melanoma-case-long-term-complete-response-treatment-cessation

Internet

http://www.drugsincontext.com/treatment-combined-dabrafenib-trametinib-brafv600e-mutated-metastatic-malignant-melanoma-case-long-term-complete-response-treatment-cessation

Similar Items